1 |
‘Randomized’ in The title or abstract |
Study identified as a randomized controlled in the title or abstract |
63 |
100 |
1.00 |
1.00 |
2 |
Background |
Adequate description of the scientific background and explanation of rationale |
17 |
27 |
0.82 |
0.66 to 0.97 |
3 |
Trial design |
Description of trial design (such as parallel, factorial) including allocation ratio |
4 |
6 |
1.00 |
1.00 |
4 |
Participants |
Description of the eligibility criteria for participants |
50 |
79 |
0.58 |
0.28 to 0.87 |
5 |
Interventions |
Details of the interventions intended for each group |
54 |
86 |
0.77 |
0.52 to 1.02 |
6 |
Outcomes |
Definition of primary (and secondary when appropriate) outcome measures |
49 |
78 |
0.79 |
0.60 to 0.99 |
7 |
Sample size |
Description of sample size calculation |
1 |
2 |
1.00 |
1.00 |
12 |
Statistical methods |
Description of the statistical methods used to compare groups for primary outcomes, subgroup analyses, or adjusted analyses |
49 |
78 |
0.85 |
0.69 to 1.02 |
13 |
Flow chart |
Details on the flow of participants through each stage of the trials (number of patients randomly assigned, receiving intended treatment, completing the protocol and analyzed) |
59 |
84 |
0.85 |
0.56 to 1.14 |
14 |
Recruitment |
Dates defining the periods of recruitment and follow-up |
38 |
60 |
0.59 |
0.37 to 0.81 |
17 |
Outcomes and estimation |
For each primary and secondary outcome, a summary of results for each group is given, and the estimated effect size and its precision (for example, 95% CI) |
53 |
84 |
0.71 |
0.44 to 0.99 |
18 |
Ancillary analyses |
Clear statement of whether subgroup/adjusted analyses were prespecified or exploratory |
0 |
0 |
1.00 |
1.00 |
19 |
Harms |
Description of all important adverse events in each group |
2 |
3 |
1.00 |
1.00 |